Oral Wegovy in Australia: TGA Approval Guide

Oral Wegovy is approved in Australia: the Therapeutic Goods Administration (TGA) officially approved oral Wegovy (semaglutide) on 3 November 2026. The approval is for chronic weight management and reducing cardiovascular risk in eligible adults. TGA approval, however, doesn’t mean the tablets are already available at pharmacies or subsidised through the PBS.

It’s reasonable to want a clear answer about what this approval means in practice. Wegovy is available in Australia on private prescription and isn’t PBS-subsidised. The PBAC has recommended a PBS listing for a limited group of people with obesity and established cardiovascular disease, but the listing process hasn’t been completed.

This guide explains the difference between TGA approval, a PBAC recommendation and an active PBS listing. It also covers prescription and eligibility requirements, what approval means for pharmacy supply, and how Wegovy differs from Ozempic, so you can understand the current position before considering treatment.

Australian registration of oral semaglutide

Australia’s Therapeutic Goods Administration (TGA) approved registration of oral Wegovy on 3 November 2026. The decision covers four tablet strengths and specified treatment uses, but registration is separate from PBS subsidy and pharmacy supply.

TGA Registration Status

TGA registration means oral Wegovy has been assessed and approved for use in Australia under its registered conditions. The TGA approved the tablet in 1.5 mg, 4 mg, 9 mg and 25 mg strengths. This makes it the first GLP-1 medicine approved by the TGA in oral form.

The four strengths identify the registered tablet presentations, not separate medicines or indications. They don’t determine an individual’s dose or treatment schedule. Prescribing in Australia should follow the final Australian Product Information, which sets out approved directions and relevant clinical information. Registration also doesn’t mean every strength is immediately stocked by pharmacies.

These distinctions matter when interpreting approval news. The registration decision establishes whether the medicine is approved for its stated use. It doesn’t confirm PBS subsidy or immediate pharmacy availability. Those are separate questions, so a TGA approval announcement shouldn’t be read as a change to the medicine’s funding status.

Registered Indication

The registered indication describes the health condition and treatment purpose for which a medicine is approved. Oral Wegovy is registered for chronic weight management and reducing the risk of major adverse cardiovascular events in eligible adults. This defines the tablet’s intended clinical use, rather than making it a general treatment for every condition associated with semaglutide.

For chronic weight management, the stated adult criteria include a BMI of 30 kg/m² or above, or a BMI of 27 kg/m² or above with a weight-related comorbidity. These thresholds help explain who may fall within the approved use. They don’t establish that treatment is appropriate for every person who meets a threshold; a prescriber considers the person’s health and circumstances.

Diabetes is a separate context. Rybelsus is TGA-approved in Australia for type 2 diabetes only, while the oral Wegovy registration covers chronic weight management and cardiovascular risk reduction in eligible adults. The brand and indication therefore matter when identifying which semaglutide medicine is being discussed.

ARTG Entry

The Australian Register of Therapeutic Goods (ARTG) is the register used to record therapeutic goods approved for supply in Australia. An ARTG entry identifies the registered product and its approved details. For oral Wegovy, the relevant registration is for tablets in 1.5 mg, 4 mg, 9 mg and 25 mg strengths.

The ARTG entry helps distinguish the registered oral product from injectable Wegovy and other semaglutide brands. Dosage form matters: approval for tablets doesn’t mean the injectable product and tablet have identical directions. Australian prescribing should follow the final Australian Product Information for the oral formulation.

An ARTG entry also shouldn’t be confused with a PBS listing. Registration concerns approval for the medicine’s stated use; PBS listing concerns subsidy. Wegovy isn’t PBS-subsidised, and the listing process remains underway. Its registration confirms its Australian regulatory status, not a PBS co-payment price or immediate availability at every pharmacy.

Prescription and eligibility requirements

Oral Wegovy requires a doctor’s prescription in Australia. TGA approval sets the medicine’s authorised use, but it doesn’t issue a prescription to an individual. For chronic weight management, the stated adult BMI thresholds are 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity.

These thresholds describe two different eligibility pathways. An adult with a BMI of 30 kg/m² or above meets the stated BMI threshold without the additional comorbidity condition in the second pathway. At a BMI of 27 kg/m² or above, at least one weight-related medical condition is part of the stated criteria. Someone below either threshold doesn’t meet these particular criteria.

BMI is a threshold in the indication, not a prescription on its own. A doctor assesses a person’s clinical circumstances and whether treatment is appropriate for chronic weight management. Weight-loss treatment involves more than matching a number to a threshold: prescribing follows an individual medical assessment, rather than happening automatically after an online request or because the medicine is registered.

Any Australian-registered GP can prescribe Wegovy privately for an eligible patient. A specialist referral isn’t required to discuss a prescription with a GP. The GP can consider the eligibility criteria and the patient’s health information. A prescription is still required before a pharmacy can supply Wegovy.

The prescribing pathway and PBS process are separate. A private prescription allows eligible patients to access Wegovy without PBS subsidy. The PBAC recommendation for a proposed listing concerns a limited population with obesity and established cardiovascular disease. It doesn’t change the BMI thresholds for TGA-approved chronic weight management or make a subsidy available now. Distinguish the treatment indication from the funding criteria.

In a consultation, the key points to discuss include:

• Whether the adult BMI threshold is met, and whether a weight-related comorbidity applies to the lower threshold.
• The person’s weight-management goals and relevant health circumstances.
• Whether a private prescription is appropriate following the doctor’s assessment.

A Weight Loss Consultation can provide a virtual setting to discuss eligibility and treatment options with an Australian-registered doctor. The consultation supports a clinical assessment; it doesn’t replace the prescription decision.

Is the Wegovy Pill Approved in Australia?

Yes. The TGA approved oral Wegovy (semaglutide) in Australia on 3 November 2026. That decision covers the tablet’s registered use, but it doesn’t make a prescription automatic or establish PBS subsidy.

Prescription Requirements

A prescription is the authorisation a patient needs before a pharmacy can supply Wegovy. An Australian-registered GP can prescribe it privately for an eligible patient, without a specialist referral. For chronic weight management, the stated adult criteria are a BMI of 30 kg/m² or above, or 27 kg/m² or above with a weight-related comorbidity. The doctor’s assessment determines whether treatment is appropriate for that patient.

Verifying the Approval Announcement

TGA approval means the medicine is registered for specified uses in Australia. Consumers can search the TGA’s Australian Register of Therapeutic Goods (ARTG) for “Wegovy” or “semaglutide” to find its entry. Check that it refers to the oral tablet rather than assuming information about injectable Wegovy applies. ARTG registration confirms approval, not PBS subsidy or pharmacy stock.

Clinical assessment is more than a BMI calculation. The GP considers the patient’s weight-management circumstances and relevant health information against the registered indication. For example, a BMI of 27 kg/m² alone doesn’t meet the stated lower threshold, which also requires a weight-related comorbidity. Meeting a threshold also doesn’t guarantee that a prescription will be issued.

The active ingredient, semaglutide, appears in more than one medicine, so the brand and dosage form matter. Oral Wegovy is a tablet; injectable Wegovy is a different form of treatment. Rybelsus is another semaglutide brand, TGA-approved in Australia for type 2 diabetes only. A patient should use the product and directions specified on their own prescription, rather than applying instructions for another brand or form.

Private prescription costs are separate from the TGA’s decision. Wegovy isn’t PBS-subsidised, so patients should expect a private prescription price rather than a PBS co-payment. The amount may depend on the prescribed strength and pharmacy supply. A PBAC recommendation for a proposed listing doesn’t create a current subsidy or set a price patients can access today.

US prescription uptake provides context, not an Australian supply forecast. Wegovy tablets exceeded three million prescriptions in the United States in just over five months after release. That figure describes US prescribing; it doesn’t establish Australian demand, pharmacy availability or local pricing. Australian patients should distinguish overseas uptake from the local registration, prescription and supply position.

Expected Australian pharmacy supply

Oral Wegovy’s TGA registration doesn’t mean Australian pharmacies have tablets ready to dispense. As of 6 November 2026, pharmacy supply was expected before the end of 2026.

That timing separates regulatory approval from the practical arrival of stock. The TGA’s decision concerns registration of the medicine; pharmacy supply also depends on release-ready product reaching the Australian market and pharmacies obtaining stock. The approved tablet strengths are 1.5 mg, 4 mg, 9 mg and 25 mg, but registration of those strengths doesn’t establish that each is available at every pharmacy.

The TGA had not yet approved Wegovy’s packaging and production processes for release, pending confirmation that they met quality standards. This is separate from approval of the medicine’s registration. It helps explain why pharmacy supply may begin after the approval announcement rather than on the approval date.

For patients, the practical point is to distinguish three stages:

• Registration: the TGA has approved oral Wegovy for its registered uses.
• Product release: packaging and production processes must meet the relevant quality standards.
• Pharmacy supply: stock must reach pharmacies before they can dispense tablets against prescriptions.

These stages don’t make the oral tablet interchangeable with injectable Wegovy. They are different dosage forms, and a prescription for one shouldn’t be treated as instructions for the other. When discussing obesity treatment, refer to the formulation and directions specified by your prescriber.

Supply timing isn’t the same as PBS access. Wegovy remains available on private prescription and isn’t PBS-subsidised. The PBAC recommendation concerns a proposed listing for people with obesity and established cardiovascular disease, subject to pricing and risk-sharing arrangements. It doesn’t mean a patient can obtain the tablet at a PBS co-payment, even after pharmacy stock arrives.

For example, a patient may have a private prescription while a pharmacy is still awaiting tablet stock. Another pharmacy may have stock once supply reaches the market, but TGA registration alone doesn’t confirm local availability. This distinction is useful when comparing oral Wegovy with an existing injection prescription or planning when to discuss a treatment change with a doctor.

Before supply begins, the final Australian Product Information remains the reference for local prescribing. It provides directions and product details relevant to Australian use. Don’t assume overseas tablet instructions apply to the Australian product. Pharmacy availability, prescription status and PBS subsidy are separate considerations, so the approval date alone doesn’t answer all three.

Oral Wegovy was expected to reach Australian pharmacies before the end of 2026. No price can be stated from the available information.

What is the TGA registration status and ARTG entry for oral Wegovy in Australia?

Oral Wegovy is registered in Australia following approval by the Therapeutic Goods Administration (TGA). Its Australian Register of Therapeutic Goods (ARTG) entry records the approved medicine and helps distinguish its regulatory status from pharmacy supply and PBS subsidy.

The ARTG is Australia’s register of therapeutic goods approved for supply. A medicine’s entry is a regulatory record, not a prescription or a funding decision. Oral Wegovy is registered as tablets in 1.5 mg, 4 mg, 9 mg and 25 mg strengths. These strengths describe the registered presentations, not an individual patient’s prescribed dose.

To identify the oral product, search the ARTG for the medicine name and check that the result refers to Wegovy tablets. Don’t rely on an entry or information for an injection when assessing the oral formulation. Dosage form matters because registration of a tablet doesn’t make it interchangeable with injectable Wegovy or another semaglutide brand.

The registered uses include chronic weight management and reducing the risk of major adverse cardiovascular events in eligible adults. Read the ARTG record alongside the Australian Product Information, which provides product-specific directions and clinical details. The register establishes which medicine and formulation are approved; the Product Information informs prescribing and use.

Three separate Australian processes can be easy to confuse:

• TGA registration: the medicine is approved for its registered uses.
• Prescription: a doctor assesses the patient and may prescribe privately when appropriate.
• PBS listing: subsidy applies only after a listing takes effect.

Wegovy isn’t PBS-subsidised. The PBAC has recommended a proposed listing for a limited group with obesity and established cardiovascular disease, subject to pricing and risk-sharing arrangements. That recommendation doesn’t mean patients can access Wegovy at a PBS co-payment. Ozempic is the semaglutide brand identified in official PBS entries for specific diabetes indications; that listing doesn’t subsidise Wegovy for weight loss.

For a patient considering treatment, the practical sequence is to identify the oral Wegovy entry, review the Australian Product Information, then discuss suitability with a prescribing doctor. Registration clarifies the product’s Australian status, while clinical assessment remains relevant to an individual prescription. To discuss prescription suitability, arrange an online medical consultation.

Aussie Scripts

Aussie Scripts offers online healthcare services to help you understand the prescription process after TGA approval. If you need a routine prescription, you can use its Standard Script or Express Script service. You’ll be assessed by an Australian-registered doctor, who decides whether a prescription is appropriate for your circumstances. A request doesn’t guarantee a Wegovy prescription, and the current PBS status is separate from that assessment.

If you’re deciding what to do next, focus on the question you need answered: prescription suitability, a routine script or a specialist referral. Aussie Scripts also offers Medical Certificates and Specialist Referrals. Choose the service that best fits your healthcare need.

Prepare for Your Next Treatment Discussion

With the TGA having officially approved oral Wegovy (semaglutide) on 3 November 2026, your next step can be a focused discussion about whether treatment fits your circumstances. Before speaking with a doctor, note your weight-management goals, relevant health history and current medicines. This gives the consultation a practical starting point without assuming that approval means a prescription is right for everyone.

Prepare questions about the oral formulation, the Australian Product Information and how pharmacy supply affects your plans. If you’re comparing a tablet with an injection, ask about the differences relevant to your treatment discussion. Keep the focus on your needs and the medical advice you receive.

Aussie Scripts offers online healthcare services for Australians seeking help with prescription-related questions. Discuss your next step with Aussie Scripts and approach your treatment decision with clear, relevant information.

Frequently Asked Questions

Is a daily pill easier than a weekly GLP-1 injection?

The practical choice depends on which routine suits you. A tablet avoids an injection but requires a daily habit; injectable Wegovy follows a weekly schedule. Consider what fits your morning routine, your comfort with injections and your ability to follow each formulation’s directions. Neither format is automatically easier for every patient. Discuss the practical differences with your prescriber before starting or changing treatment.

What Are the Side Effects of Oral Wegovy?

Check the Australian Product Information for the full list of side effects and warnings for oral Wegovy. Details are specific to the registered product and formulation, so don’t rely on information for another semaglutide brand or an overseas tablet. Before treatment, discuss your health history and other medicines with your prescriber. Seek medical advice if you experience a concerning reaction while taking it.

What Is Wegovy and How Does It Work?

Wegovy is a semaglutide medicine used for chronic weight management in eligible adults. Oral Wegovy delivers the active ingredient as a tablet, while injectable Wegovy delivers it by injection. Semaglutide belongs to the GLP-1 medicine class. The tablet and injection have different directions, so use the formulation prescribed for you. A prescriber can explain how treatment fits your health needs and goals.

How Should Wegovy Tablets Be Taken?

Follow the final Australian Product Information and the directions on your prescription. Overseas instructions describe taking one tablet on waking with a sip of plain water, then waiting before food, drinks or other oral medicines. They also specify a water limit. Don’t assume these are the Australian directions; follow the locally approved product information. Ask your prescriber or pharmacist about any unclear instruction.

How does this compare with injectable Wegovy?

Both formulations contain semaglutide, but one is a tablet and the other an injection. The tablet is taken daily, while injectable Wegovy is administered weekly. Their directions and strengths aren’t interchangeable, so anyone moving between formulations needs prescribing guidance, not a simple substitution. Discuss with your doctor why you’re considering a change, including your routine preferences.

Is Wegovy Actually Available in Australian Pharmacies?

Pharmacy supply is a separate step from TGA registration. Australian supply of the oral tablet was expected before the end of 2026, but registration alone doesn’t mean a particular pharmacy has stock. Wegovy is available on private prescription and is not PBS-subsidised. A PBAC recommendation for a proposed listing isn’t an active subsidy. Ask your pharmacist about local stock after receiving a prescription.

Did the TGA approve oral Wegovy (semaglutide) in Australia on 3 November 2026?

Yes. The TGA approved registration of oral Wegovy in Australia on 3 November 2026. The approval covers the tablet formulation in 1.5 mg, 4 mg, 9 mg and 25 mg strengths. It confirms the medicine’s Australian regulatory status, not immediate stock at every pharmacy or PBS subsidy. Those are separate matters from the TGA’s registration decision.

What condition and patient group is oral Wegovy approved to treat in Australia?

Oral Wegovy is approved for chronic weight management in eligible adults and for reducing the risk of major adverse cardiovascular events in eligible adults. For chronic weight management, the stated criteria include a BMI of 30 kg/m² or above, or 27 kg/m² or above with a weight-related comorbidity. These criteria describe the approved use; a prescriber assesses whether treatment is suitable for an individual.